177Lu Dotatate (Lutathera) is a radiolabeled somatostatin analog peptide approved by the FDA for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Specifically, 177Lu Dotatate is indicated for:
- Unresectable or metastatic GEP-NETs
- Progressive, well or moderately differentiated GEP-NETs
- Positive somatostatin receptor expression based on immunohistochemistry or other tests
Some key points about the FDA approval of 177Lu Dotatate:
- The approval was based on the NETTER-1 phase III clinical trial which demonstrated improved progression-free survival with 177Lu Dotatate compared to high-dose octreotide LAR in patients with midgut NETs.
- 177Lu Dotatate binds to somatostatin receptors (particularly sst2) which are overexpressed on NET cells, thereby delivering targeted radiation therapy.
- Common side effects include nausea, vomiting, lymphopenia, increased GGT, increased AST, increased ALT, increased blood glucose, and increased triglycerides. Serious side effects can include myelosuppression, renal toxicity, hepatic toxicity, and acute leukemia.
- Treatment involves 4 intravenous injections of 7.4 GBq doses at 8-week intervals along with kidney protection agents and anti-emetics.
At
Hormone Harmony, we offer cutting-edge diagnostic testing and treatment services for various hormone-related conditions, including NETs and other neuroendocrine disorders. Our clinic is equipped with the latest technologies, including:
- PET/CT scanners to accurately visualize and characterize NETs
- Targeted radionuclide imaging to determine somatostatin receptor status
- Access to 177Lu Dotatate therapy through our partnership with specialized centers
- Genetic testing to understand hereditary risk factors for NETs
- Advanced hormone lab for tumor marker assessments and functional disease characterization
- Multidisciplinary care team including endocrinologists, radiologists, nuclear medicine physicians, oncologists, and specialty nurses to develop individualized treatment plans
If you or a loved one has been diagnosed with a GEP-NET or other neuroendocrine tumor, consider being evaluated at our center to determine if 177Lu Dotatate PRRT may be an appropriate treatment option. We are committed to giving you the answers, care, and hope you deserve.
